NeuroStar® TMS Advances Treatment for Adolescents During Mental Health Awareness Month

May 1, 2024

https://www.globenewswire.com/news-release/2024/05/01/2873255/0/en/NeuroStar-TMS-Advances-Treatment-for-Adolescents-During-Mental-Health-Awareness-Month.html

MALVERN, Pa., May 01, 2024 (GLOBE NEWSWIRE) —  Neuronetics, Inc. (NASDAQ:STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, is committed to supporting adolescents facing major depressive disorder (MDD). NeuroStar TMS (transcranial magnetic stimulation) is uniquely poised to significantly impact the mental health landscape for young individuals following the recent clearance from the U.S. Food and Drug Administration (FDA) for NeuroStar’s use as a first-line add-on for adolescents aged 15-21 with MDD.

Read more at globenewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.